

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.
上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

**POLL RESULTS OF
THE 2021 ANNUAL GENERAL MEETING HELD ON JUNE 27, 2022;
RESIGNATION OF NON-EXECUTIVE DIRECTOR;
AMENDMENTS TO THE ARTICLES OF ASSOCIATION;
AND ADOPTION OF THE 2022 H SHARE INCENTIVE SCHEME**

The Board is pleased to announce that all the resolutions set out in the Notice of AGM were duly passed by the Shareholders by way of poll at the AGM.

The 2021 annual general meeting (the “**AGM**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) was convened at 2:00 p.m. on Monday, June 27, 2022 at Fourth Floor, Building 7, 59 Kaiqing Road, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, PRC. Reference are made to the notice (the “**Notice of the AGM**”) and the circular (the “**Circular**”) of the AGM of the Company both dated May 20, 2022. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The AGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and chaired by Mr. Philip Li Wang, the Chairman of the Board and an executive director of the Company.

ATTENDANCE AT THE AGM

As at the date of the AGM, the total number of issued ordinary shares (“**Shares**”) of the Company was 243,937,000 Shares, comprising 61,606,116 H Shares, 100,107,425 Domestic Shares and 82,223,459 Unlisted Foreign Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against or abstain from voting on the proposed resolutions at the AGM.

Shareholders (including proxies) representing 128,023,403 Shares (including 7,676,684 H Shares, 63,319,211 Domestic Shares and 57,027,508 Unlisted Foreign Shares) or approximately 52.48% of the total issued Shares of the Company attended the AGM.

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the AGM as set out in Rule 13.40 of the Hong Kong Listing Rules; (2) no Shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the AGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

All directors of the Company, namely Mr. Philip Li Wang, Mr. Yunqing Wang, Ms. Li Cai, Mr. Quan Zhou, Mr. Jie Yin, Mr. Ji Chen, Mr. Charles Sheung Wai Chan, Mr. Xubo Lu and Mr. George Chien Cheng Lin, attended the AGM either in person or by electronic means.

POLL RESULTS OF THE AGM

The poll results of the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the work report of board of directors of the Company for 2021.	128,023,403 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the work report of supervisory committee of the Company for 2021.	128,023,403 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the profit distribution plan for 2021.	128,023,403 (100%)	0 (0%)	0 (0%)
4.	To consider and approve the audited consolidated financial statements of the Company for 2021.	128,023,403 (100%)	0 (0%)	0 (0%)
5.	To consider and approve the annual report of the Company for 2021.	128,023,403 (100%)	0 (0%)	0 (0%)
6.	To authorise the Board to determine the remuneration of the Directors.	128,023,403 (100%)	0 (0%)	0 (0%)
7.	To authorise the Supervisory Committee to determine the remuneration of the supervisors of the Company.	128,023,403 (100%)	0 (0%)	0 (0%)

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
8.	To consider and approve the re-appointment of Ernst & Young as the auditors of the Company for a term until the conclusion of the next annual general meeting of the Company and to authorise the Board to determine its remuneration.	128,023,403 (100%)	0 (0%)	0 (0%)
Special Resolutions		Number of votes (%)		
		For	Against	Abstain
9.	To consider and approve the proposed amendments to the Articles of Association.	128,023,403 (100%)	0 (0%)	0 (0%)
10.	To consider and approve the proposed adoption of the 2022 H Share Incentive Scheme.	128,023,403 (100%)	0 (0%)	0 (0%)
11.	To consider and approve the proposed authorization to the Board and/or the Delegatee to handle matters pertaining to the 2022 H Share Incentive Scheme.	128,023,403 (100%)	0 (0%)	0 (0%)
12.	To consider and approve issue additional H shares, additional domestic shares, and additional unlisted foreign shares in the share capital of the Company and to grant the Board a general mandate to issue additional shares (the full text of the resolution is set out in the Notice of Annual General Meeting).	128,023,403 (100%)	0 (0%)	0 (0%)

Note: All percentages are rounded to two decimal places.

As more than half of the votes were cast in favour of Ordinary Resolutions No. 1 to No. 8, and two-thirds of the votes were cast in favour of Special Resolutions No. 9 to No. 12, all resolutions proposed at the AGM were duly passed by way of poll by the Shareholders. The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

Reference is made to the announcement of the Company dated May 12, 2022, Mr. Jie YIN (陰杰) (“**Mr. Yin**”) resigned as a non-executive Director with effect from the conclusion of the AGM. Mr. Yin has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the announcement of the Company dated May 12, 2022 and the Circular, in relation to (among other things) the proposed amendments to the Articles of Association. The proposal in relation to the amendments to the Articles of Association has been duly approved by Shareholders at the AGM by way of special resolution.

ADOPTION OF THE 2022 H SHARE INCENTIVE SCHEME

Reference is made to the announcement of the Company dated May 11, 2022 and the Circular, in relation to (among other things) the proposed adoption of the 2022 H Share Incentive Scheme. The proposal in relation to the adoption of the 2022 H Share Incentive Scheme has been duly approved by Shareholders at the AGM by way of special resolution.

By order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive director

Shanghai, the People’s Republic of China, June 27, 2022

As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive director, Mr. Yunqing WANG as executive director, Ms. Li CAI, Mr. Quan ZHOU, and Mr. Ji CHEN as non-executive directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive directors.